TNFSF11 and breast cancer: Therefore, the blockade of RANKL via Dmab could inhibit the promitogenic role of progesterone, rationalizing its use as a candidate for drug repurposing in oncology, including breast cancer, beyond skeletal-related event (SREs) prevention.